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Abstract
Background: We have previously shown that diabetic rats are more susceptible to sepsis, but that the Acute lung
injury (ALI) secondary to sepsis is less intense than in non-diabetics. In the present study, we further investigated
the ALI-secondary to sepsis in diabetic rats and the effect of insulin treatment.
Methods: Diabetes was induced in male Wistar rats by alloxan and sepsis by cecal ligation and puncture surgery
(CLP). Some diabetic rats were given neutral protamine Hagedorn (NPH) insulin (4 IU, s.c.) 2 h before CLP. Six h
later, the lungs were examined for edema, cell infiltration and prostaglandin-E2 (PGE2) levels in the bronchoalveolar
lavage (BAL).
Results: The results confirmed that leukocyte infiltration and edema were milder in diabetic rats with sepsis. After
insulin treatment, the lung inflammation in diabetics increased to levels comparable to the non-diabetics. The BAL
concentration of PGE2 was also lower in diabetics with sepsis, and increased after insulin treatment. Sepsis was
followed by early fibroblast activation in the lung parenchyma, evaluated by increased transforming growth factor
(TGF)-β and smooth muscle actin (α-SMA) expression, as well as an elevated number of cells with myofibroblasts
morphology. These events were significantly lower in diabetic rats and increased after insulin treatment.
Conclusion: The results show that insulin modulates the early phase of inflammation and myofibroblast
differentiation in diabetic rats.
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Background
Sepsis is associated with a systemic inflammatory re-
sponse that affects several organs [1]. The lung is par-
ticularly affected and develops an acute lung injury
(ALI) that increases the morbidity and mortality of sep-
sis. Indeed sepsis is the predisposing condition with the
highest risk of progression into ALI that starts with lung
vascular endothelium injury [2,3].
ALI has been traditionally divided into three phases,
starting with an acute inflammation with leukocyte infil-
tration, edema and inflammatory mediators production.
This is followed by a fibroproliferative phase within 5 to
7 days, when fibroblasts-like mesenchymal cells replicate
and secrete extracellular matrix proteins such as colla-
gens. In the final phase, interstitial and intra-alveolar
fibrosis are established [3]. Even though the fibroproli-
ferative phase has traditionally been regarded as a late
event, some studies have questioned this view. A marker
of collagen turnover, N-terminal procollagen peptide
type III (N-PCP-III) was found in high levels in bron-
choalveolar lavage fluid (BALF) and tracheal aspirate
from patients within 24 h of ALI diagnosis [4-7]. Also,
the BALF collected at this time point showed a potent
mitogenic activity in cultured lung fibroblast [6]. In ani-
mal models, both pulmonary and extra-pulmonary ALI
presented increased collagen fiber content at 24 h [2].
These data suggest that the fibrogenic pathway in ALI
starts early after the stimulus.
In the lung, fibroblasts are thought to be the major cell
responsible for collagen synthesis and soluble mediators
play a central role in its activation [8]. The Transforming
Growth Factor (TGF)-β, which is produced in ALI,
is a classical fibroblasts activator that leads to its
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differentiation into myofibroblasts expressing α-smooth
muscle actin (α-SMA) [9]. It was demonstrated that
BALF from early-diagnosed ALI patients induce in vitro
fibroblast differentiation into myofibroblasts and this
was partially attributed to TGF-β [7]. Moreover, in early
ALI, myofibroblasts were found in hyaline membranes
in human patients [10,11].
It is well known that diabetic patients present several
immunological dysfunctions that increase their suscepti-
bility to infection and mortality to sepsis [12-14]. This is
partially reversed by insulin treatment [14]. Despite the
increased susceptibility to sepsis, diabetic patients are
less likely to develop ALI [15-18]. In an animal model of
ALI secondary to sepsis we have found that the lung in-
flammation was milder in diabetics [19]. The aim of the
present study was to investigate the effect of insulin
treatment in the ALI secondary to sepsis in diabetic rats.
To this purpose, we used the established CLP (cecal
ligation and puncture) model of sepsis, and examined
the lung edema, cell infiltration, PGE2 production and
early fibroblast activation.
Methods
Animals
Specific pathogen-free male Wistar rats weighing 200 ±
20 g at the beginning of experiments were used. Animals
were maintained at 23 ± 2°C under a 12 h light–dark
cycle and were allowed access to food and water ad
libitum.
Ethics statement
This study was carried out according to the care and
use of experimental animals guideline of Canadian
Council on Animal Care (CCAC) and Brazilian Col-
lege of Animal Experimentation. The protocol was ap-
proved by the Ethical Committee for Animal Research
of the Biomedical Sciences Institute, University of São
Paulo (PermitNumber: 139-65-02). All surgeries were
performed under ketamine anesthesia, and all efforts
were made to minimize suffering.
Alloxan-induced diabetes
Diabetes mellitus was induced by an intravenous injec-
tion in the tail vein of 42 mg/Kg of alloxan monohydrate
(Sigma Chemical Co., St. Louis, MO, USA) dissolved
in physiological saline (0.9% NaCl). Control rats were
injected with physiological saline only. Ten days later,
the presence of diabetes was verified by blood glucose
concentrations above 200 mg/dL, which was determined
with the aid of a blood glucose monitor (Eli Lilly, São
Paulo, SP, Brazil) in samples obtained from the cut tip of
the rat tail.
Sepsis-induced ALI
A total of 35 rats were randomly assigned into five
groups of seven animals each: non-diabetic SHAM or
CLP, and diabetic SHAM, CLP or insulin-treated CLP.
Animals were anesthetized with an intraperitoneal injec-
tion (150 mg/Kg) of ketamine hydrochloride (Ketamin-S
(+); Cristalia, São Paulo, Brazil). A midline laparotomy
was performed, and the cecum was exposed, ligated and
punctured 12 times with a 20-gauge needle in rats of the
CLP groups. The cecum was replaced in the abdomen
and the incision was closed [19]. Animals of the SHAM
groups were subjected to midline laparotomy and ma-
nipulation of the cecum without ligation and puncture.
The insulin-treated diabetic animals received 4 IU of
neutral protamine Hagedorn (NPH) insulin (Eli Lilly,
São Paulo, SP, Brazil) subcutaneously, 2 h before the
CLP procedure since the maximum serum concentration
(Cmax) of NPH insulin was reached between 6 and 8 h
after administration. After surgery, the animals were
returned to their cages and allowed access to food and
water ad libitum. Six h after CLP, the animals were anes-
thetized, as described previously, and exsanguinated
from the abdominal aorta. After bronchoalveolar lavage
(BAL) performed with 10 mL of phosphate-buffered sa-
line (PBS), the lungs were removed, rinsed and the lobu-
lated side immediately immersed in 10% buffered
formalin for histology and immunohistochemistry.
Cell count
The recovered BAL samples were centrifuged (500 × g
for 15 min), re-suspended in PBS, and total cell counts
were performed under light microscopy (Olympus BX51,
Olympus Latin America, São Paulo, Brazil).
Prostaglandin-E2 (PGE2) measurement
The PGE2 level was measured in the BAL supernatant
with enzyme immunoassay (EIA) using a commercial kit
from Cayman Chemical (Ann Harbor, MI, USA) follow-
ing the manufacturer’s protocol.
Protein measurement
Protein concentrations were determined in the BAL
supernatant, as a measure of edema, with a commercially
available kit (BCA™ Protein Assay Kit, Pierce Biotechnol-
ogy Inc., Rockford, IL, USA) following the manufacturer’s
protocol.
Immunohistochemistry
Lung sections were subjected to paraffin removal proce-
dures, hydrated, and antigenic retrieval was performed
by incubating the slides in 10 mM sodium citrate buffer,
pH 6.0, 0.05% Tween 20, at 90°C for 20 min. Each suc-
cessive step was followed by a thorough rinse in PBS. All
steps were performed in a humidified chamber. Slides
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were then treated with 3% H2O2 in PBS for 30 min to
block endogenous peroxidase activity. Nonspecific staining
was blocked by incubating the sections for 30 min in PBS
containing 10% BSA. Rabbit polyclonal anti-α-SMA anti-
body (ab5694, abcam) was diluted 1:200 and rabbit poly-
clonal anti-TGF-β (600-401-432, Rockland, Gilbertsville,
PA) 1:100 in PBS containing 0.3% Tween 20 and incu-
bated overnight at 4°C. The sections were incubated with
biotin-conjugated goat anti-rabbit immunoglobulin G
(Vector Laboratories, Burlingame, CA), diluted 1:1,000
in PBS, for 1 h at room temperature. After washes in
PBS, sections were incubated in streptavidin-peroxidase
ABC complex (Vector Laboratories) for 1 h at room
temperature. Peroxidase was visualized using 0.03% 3,3′-
diaminobenzidine in PBS with 0.03% H2O2. The sections
were counterstained with Mayer’s hematoxylin. For each
immunohistochemical reaction, controls were obtained by
omitting the primary antibody.
Staining quantification
The material was analyzed under a Nikon Eclipse E600
microscope, and images were captured using a Nikon
DXM1200C digital camera at a magnification of x400
for TGF-β and x1,000 for α-SMA. Photographs were an-
alyzed and morphometric analysis performed using the
NIS Elements AR 2.30 Imaging Software. We quantified
the stained area in 10 random non-coincident micro-
scopic fields of the lung parenchyma in each slide (one
slide/animal). The areas of staining of each animal were
averaged and this number was considered representative
of that individual animal. Results are presented as the
mean of the stained area in square micrometers.
Histology
Lungs were dehydrated in 70% ethanol, processed using
standard procedures and embedded in paraffin. Sections
of 5 mm were cut, mounted on slides, and stained with
hematoxylin and eosin.
Morphometric analysis of elongated cells
Lung morphometric analysis was performed with an in-
tegrating eyepiece and a coherent system consisting of a
grid with 100 points and 50 lines (known length)
coupled to a conventional light microscope (Olympus
BX51, Olympus Latin America, São Paulo, Brazil). Elon-
gated fusiform cells were evaluated at x1,000 magnifica-
tion, and 10 random, non-coincident microscopic fields
of lung parenchyma in each slide (one slide/animal) were
evaluated for each group, n = 7 per group. Points falling
on elongated cells were identified by conventional morph-
ology, counted and divided by the total number of points
falling on the tissue area in each microscopic field as de-
scribed by Menezes et al. [2].
Statistical analysis
Data are presented as means ± SEM and analyzed by
Student’s t-test or ANOVA followed by the Tukey-Kramer
multiple comparison test when appropriate. P <0.01 was
considered significant.
Results
Alloxan is a cytotoxic glucose analogue that preferen-
tially accumulates in pancreatic β-cell and generates re-
active oxygen species thus, promoting β-cell destruction.
Alloxan treatment results in insulin-dependent diabetes
that has largely been used as an animal model of type 1
diabetes [20]. Regarding the general characteristics of
the experimental model of ALI secondary to sepsis,
compared to controls, alloxan-treated diabetic rats ex-
hibited a significant reduction in body weight gain
(values, mean ± SEM, control: 60 ± 2 g, n = 12; diabetic:
21 ± 9 g, n = 12, p <0.001) during the 10-day period
before the surgery, while the blood glucose levels were
elevated (control: 97 ± 16 mg/dL, n = 6; diabetic: 534 ±
62 mg/dL, n = 5; p <0.0001). After treatment with a sin-
gle dose of NPH insulin, diabetic rats exhibited a signifi-
cant reduction in blood glucose levels (102 ± 77 mg/dL,
n = 5, p <0.0001).
Lung inflammation was examined 6 h after sepsis by
measuring leucocyte infiltration, edema and PGE2 levels
in the BAL. Figure 1A shows that non-diabetic rats with
sepsis presented a significant inflammatory cell infiltra-
tion in the alveolar space compared to the sham group.
However, in diabetic animals the cell infiltration was sig-
nificantly lower. Insulin treatment of diabetic rats re-
stored the number of inflammatory cells infiltrating the
alveolar space to numbers close to that seen in the non-
diabetic animals. Lung edema was evaluated as increased
protein concentration in the BAL. In non-diabetic rats,
sepsis induced more than a two-fold increase in BAL
protein extravasation compared to diabetic animals.
After insulin treatment of diabetic rats, the protein con-
centration was restored to levels similar to those in non-
diabetic animals (Figure 1B). Diabetic rats exhibited 4
times less PGE2 in the BAL compared to non-diabetics.
CLP did not increase PGE2 levels in either diabetic or
non-diabetic rats. Insulin treatment restored PGE2 con-
centration in diabetics to the levels of the non-diabetic
rats (Figure 1C). These results confirm our previous
findings that diabetic rats develop milder lung inflamma-
tion induced by sepsis than non-diabetic animals [19]
and that insulin treatment restores the inflammatory re-
sponse in diabetics to that of non-diabetics.
There is some evidence that fibroproliferation occurs
very early in the lungs of ALI/ARDS patients [6,7].
Therefore, we investigated fibroblast activation and dif-
ferentiation into myofibroblast in our ALI model, com-
paring diabetics with non-diabetics and the effect of
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insulin treatment. (TGF)-β is a cytokine known to acti-
vate fibroblasts and is largely produced by several cell
types present in the lungs [8,21]. When we investigated
TGF-β expression in the lung parenchyma after 6 h of
CLP by immunohistochemistry, we found that sham-
operated non-diabetic and diabetics animals showed
similar basal expression of this cytokine. After CLP, the
positive staining increased in both groups, but this was
significantly lower in diabetic animals compared with
non-diabetic animals (Figure 2A). In the diabetic CLP
group, insulin treatment increased TGF-β expression.
The positive staining was homogenous in the lung par-
enchyma and the quantification confirmed the pattern
observed (Figure 2B).
The activated fibroblast differentiates into cells that
express the contractile α-SMA protein [9]. Even though
α-SMA can be found in the lungs around the bronchi,
bronchia, trachea and blood vessels, expressed by muscle
cells or myofibroblasts, the expression of this protein in
the lung parenchyma is restricted to myofibroblasts
[22-25]. The expression of α-SMA in lung parenchyma
of non-diabetic and diabetic rats was low or absent,
but after 6 h of CLP, there was a significant increase in
α-SMA expression in both diabetic and non-diabetic
rats, which was less intense in diabetics. Insulin treat-
ment restored the α-SMA expression in diabetics
to similar levels found in non-diabetics after CLP
(Figure 3A). The same pattern was observed when the
α-SMA expression was quantified (Figure 3B). The
measurement of positive staining was performed ex-
clusively in the lung parenchyma.
The lung parenchyma cells that express α-SMA are
myofibroblasts and they usually have an elongated morph-
ology [22,26]. The non-diabetic rats with sepsis showed a
diffuse but significant number of cells with this morph-
ology. Morphometric analysis was performed (10 different
random fields of the parenchyma were evaluated for each
animal and 7 animals per group - Figure 3C). After 6 h of
CLP, the number of elongated cells in non-diabetic rats in-
creased compared to the sham group. The CLP procedure
also elevated the number of elongated cells in diabetic
lungs, but this was lower than in the non-diabetic CLP
rats. Insulin treatment restored the number of elongated
cells in diabetic animals to values close to that of non-
diabetic rats with CLP.
Discussion
We previously showed that ALI secondary to sepsis was
milder in alloxan-induced diabetic rats and involved the
adaptor molecule of the IL-1 receptor family (which in-
cludes TLR-4), MyD88 [19]. In the present study, we
confirmed that lung inflammation (edema, cell infiltra-
tion and PGE2 production) was milder in diabetics using
the same model of the previous work, ALI secondary to
sepsis induced by CLP. We also found evidence of early
fibroblast activation: increased TGF-β and α-SMA ex-
pression and an elevated number of cells with morph-
ology similar to that of myofibroblasts (elongated cells)
in the lung parenchyma. Diabetic animals displayed less
intense fibroblast activation compared to non-diabetic
rats. Insulin treatment of diabetic rats restored the in-
flammatory response (edema, cell infiltration, PGE2), as
well as the early fibroblast differentiation in myofibro-
blast (TGF-β and α-SMA levels and elongated cells).
PGE2 is a lipid mediator of inflammation and it is
overproduced in sepsis-induced ALI, enhancing lung in-
jury and inflammation [27]. In our experiments, the
levels of PGE2 in the BALF of rats with sepsis did not
increase and remained similar to basal levels in non-
diabetics as well as in diabetic rats. This divergence can
be explained by the difference in the time after sepsis
ALI was analyzed, since we used an earlier time point.
Figure 1 Effect of insulin on sepsis-induced ALI. Non-diabetic, diabetic and insulin-treated diabetic rats were subjected to CLP or SHAM
(false operated) surgery and after 6 hours the BAL was collected. (A) Total leukocyte count in the BAL was determined under light microscopy.
(B) Edema was assessed as increased protein concentration in the BAL and expressed as a fold increase compared to SHAM-operated rats.
(C) PGE2 concentration was determined by ELISA. Data are presented as mean + − SEM. *p < 0.01.
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However, the basal levels of PGE2 were much lower in
diabetics and remained low after sepsis. Interestingly, in-
sulin treatment markedly increased the PGE2 levels in
diabetic rats with sepsis. We have no explanation for
these results. It is known that PGE2 is important in
maintaining homeostasis in healthy lungs [26]. A pos-
sible speculation for the lower basal levels in diabetics is
that their lungs are less prone to homeostatic regulation
and that insulin, by increasing PGE2 would restore lung
homeostatic mechanisms. Clearly, more studies are needed
to explain these results.
There are many growth factors that can induce fibro-
blast proliferation and differentiation into myofibroblasts,
but TGF-β is the most studied [9]. Although the
fibroproliferative phase of ALI has been regarded as a late
event, there is some evidence that it can start at the early
stages [5,6]. We noticed that both non-diabetic and dia-
betic rats displayed similar basal levels of TGF-β expres-
sion in the lung parenchyma, which increased 6 h after
CLP. In our model of CLP-induced ALI, we observed an in-
creased number of cells producing TGF-β and α-SMA, and
an elevation in the number of elongated cells. These param-
eters were significantly lower in diabetic rats. Insulin treat-
ment modulated this early fibroblast activation since it
increased TGF-β and α-SMA expression. Since in the lung
parenchyma, the cells expressing α-SMA are myofibroblasts
[22,26] our data indicates that in ALI secondary to sepsis,
myofibroblast differentiation occurs in very early stages.
Figure 2 Expression of TGF-β in the lung parenchyma after CLP. Non-diabetic, diabetic and insulin-treated diabetic rats were subjected to
CLP or SHAM (false operated) surgery. After 6 hours, the lungs were washed, removed and processed. The expression of TGF-β was assessed by
immunohistochemistry, positive staining in brown (diffused) and nuclei in blue (A) and morphometric analysis (B) of stained area in μm2 at 400x
magnification. Ten random non-coincident microscopic fields were evaluated for each group, n = 7/group. Scale bar =20 μm. Data are presented
as mean + −SEM. *p < 0.01.
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We had previously shown in a pulmonary model of
ALI induced by LPS that the lung inflammation in type
1 diabetic rats, measured by inflammatory cytokines,
was less intense and modulated by insulin [28]. Bellemeyer
et al. showed that type 2 diabetic mice also present
decreased lung inflammation in a model of ALI induced
by hyperoxia [29]. In the present work we found evidence
that the milder sepsis-induced ALI in diabetics is accom-
panied by lower fibroproliferation and this was increased
to non-diabetic levels with insulin treatment. However, it
Figure 3 Myofibroblast differentiation in the lung parenchyma after CLP. Non-diabetic, diabetic and insulin-treated diabetic rats were
subjected to CLP or SHAM (false operated) surgery. After 6 hours, the lungs were washed, removed and processed. The expression of α-sma was
assessed by immunohistochemistry, positive staining in brown (arrows) and nuclei in blue (A) and morphometric analysis (B) of stained area in μm2,
scale bar = 50 μm. Cells expressing a-SMA are indicated with arrows. Elongated cell index (C) was determined in the parenchyma of lung section
stained with haematoxylin-eosin. The quantification was performed with an integrating eyepiece with a coherent system consisting of a grid with 100
points and 50 lines (known length). The cells were evaluated at x1,000 magnification. Points falling on characteristic elongated fusiform cells were
counted and divided by the total number of points falling on tissue areas in each microscopic field. Ten random non-coincident microscopic fields
were evaluated for each group, n = 7/group. Data are presented as mean + −SEM. *p < 0.01.
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is not clear whether the lung fibroblasts were directly af-
fected by insulin treatment or whether this effect of insu-
lin was a consequence of its ability to modulate lung
inflammation. This subject is of interest and will be fur-
ther investigated.
In lung biopsies from patients with diffuse alveolar
damage, a hallmark of the inflammatory phase of ALI,
myofibroblasts have been found [10,11]. To this date
there is no satisfactory treatment for fibroproliferation
in septic patients; thus, understanding the mechanisms
involved in myofibroblast activation can provide an im-
portant therapeutic approach for prevention or treat-
ment of ALI in sepsis.
It is noteworthy that insulin treatment has a positive
effect in diabetics by restoring the immune response to
infections [14] and a negative effect by abolishing the
lung protection to sepsis as we showed here.
One limitation of this study is that by choosing this
protocol of severe sepsis, 6 h after CLP was the max-
imum time point when all animals were alive [19] and
thus the lung inflammation could not be analyzed at
later times.
Conclusion
In conclusion, the results presented here confirm and
extend the finding that the lungs of diabetic rats are
“protected” from secondary injury caused by sepsis and
that insulin abolishes this “protection”. Moreover, we
show that myofibroblast differentiation in the lung starts
very early after sepsis, is less intense in diabetics and
that insulin treatment increases myofibroblast differenti-
ation to the levels of non-diabetics.
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